View Clinical Trial (Medical Research Study)
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches - NCT00391755-22902(Clinical Trial 153927)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Charlottesville |
|
State:
|
|
VA |
| Zip Code: |
|
22902 |
| Conditions: |
|
Migraine Headache |
| Purpose: |
|
To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor
agonist used for insomnia, as a migraine prophylactic agent.
|
| Study summary: |
|
In a recent, large study of migraineurs, over half reported difficulties with sleep
initiation or maintenance. Those who had shorter average sleep times reported more severe
headaches. Poor sleep has been associated with increased frequency and severity of
migraines. The improvement of migraine frequency with improved sleep hygiene has been
documented.
PET imaging has shown increased regional cerebral blood flow to neural structures involved
in the sleep wake cycle during migraine headaches. Polysomnography has shown specific
headache types to occur in specific sleep stages.
Melatonin has been effective primarily in headache due to delayed sleep phase syndrome.
Recent studies support the efficacy of melatonin in treating migraine. The purpose of this
study is to examine the efficacy of Rozerem as a prophylactic migraine medication. If
effective, the benefits of the drug as a prophylactic agent for migraine include the
tolerability of the drug and the possible secondary benefit of improvement in sleep.
Hypothesis: Rozerem will decrease migraine frequency due to the improvement in sleep and
possibly due to the shared neurophysiology of sleep and migraine affected by melatonin. |
| Criteria: |
|
Inclusion Criteria:
- Age 18-65
- 3-8 Migraine headaches/month
- Able to understand and comply with the study
Exclusion Criteria:
- Currently on migraine prophylaxis
- Currently on sleep medication > 4days/month
- Currently on Fluvoxamine
- Untreated psychiatric or sleep disorders
- MRI abnormalities other than those attributable to migraine headaches
- Abnormalities on neurological exam other than known neurological disorders
unassociated with migraine or sleep
- Known disorders of prolactin
- Bipolar disorder
- Hepatic disease
- Pregnancy |
|
|
|
| Study is available at: |
|
Patricia Shipley, MD
Charlottesville, VA 22902
United States
Primary Contact:
Patricia J Shipley, MD
Email: Patricia.Shipley@MJH.org
Phone: 434-293-0866 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 21, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|